Cas:81376-53-6 4-(4-methylimidazol-1-yl)phenol manufacturer & supplier

We serve Chemical Name:4-(4-methylimidazol-1-yl)phenol CAS:81376-53-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(4-methylimidazol-1-yl)phenol

Chemical Name:4-(4-methylimidazol-1-yl)phenol
CAS.NO:81376-53-6
Synonyms:4-(4-methylimidazol-1-yl)phenol
Molecular Formula:C10H10N2O
Molecular Weight:174.19900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.05000
Exact Mass:174.07900
LogP:1.88630

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-(4-methylimidazol-1-yl)phenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(4-methylimidazol-1-yl)phenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(4-methylimidazol-1-yl)phenol Use and application,4-(4-methylimidazol-1-yl)phenol technical grade,usp/ep/jp grade.


Related News: It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. 4-(4-methylimidazol-1-yl)phenol manufacturer It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. 4-(4-methylimidazol-1-yl)phenol supplier The European Medicines Agency did not say how many shots were affected, but Reuters has reported it involves millions of doses, making it harder for J&J to meet a target of delivering 55 million to Europe by end of June. 4-(4-methylimidazol-1-yl)phenol vendor It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. 4-(4-methylimidazol-1-yl)phenol factory INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.